| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Aneurysm, Thoracic | 176 | 2026 | 695 | 37.210 |
Why?
|
| Blood Vessel Prosthesis Implantation | 123 | 2025 | 746 | 25.660 |
Why?
|
| Aorta, Thoracic | 85 | 2025 | 527 | 15.670 |
Why?
|
| Endovascular Procedures | 52 | 2025 | 786 | 10.710 |
Why?
|
| Aortic Aneurysm | 42 | 2025 | 221 | 9.780 |
Why?
|
| Vascular Surgical Procedures | 47 | 2024 | 536 | 9.310 |
Why?
|
| Postoperative Complications | 104 | 2026 | 3130 | 8.670 |
Why?
|
| Aortic Aneurysm, Abdominal | 36 | 2023 | 365 | 7.710 |
Why?
|
| Aortic Diseases | 27 | 2024 | 188 | 7.140 |
Why?
|
| Marfan Syndrome | 24 | 2023 | 146 | 6.450 |
Why?
|
| Blood Vessel Prosthesis | 44 | 2024 | 472 | 5.760 |
Why?
|
| Heart Valve Prosthesis Implantation | 30 | 2023 | 428 | 5.460 |
Why?
|
| Aorta | 34 | 2023 | 522 | 4.940 |
Why?
|
| Treatment Outcome | 178 | 2025 | 12913 | 4.880 |
Why?
|
| Aortic Valve | 33 | 2023 | 456 | 4.830 |
Why?
|
| Coronary Artery Bypass | 40 | 2025 | 516 | 4.030 |
Why?
|
| Paraplegia | 14 | 2025 | 87 | 3.410 |
Why?
|
| Stents | 30 | 2024 | 782 | 3.270 |
Why?
|
| Humans | 386 | 2026 | 130854 | 3.270 |
Why?
|
| Time Factors | 81 | 2025 | 6217 | 3.240 |
Why?
|
| Risk Factors | 104 | 2026 | 10978 | 3.220 |
Why?
|
| Retrospective Studies | 132 | 2026 | 17673 | 3.210 |
Why?
|
| Aged | 164 | 2026 | 20970 | 3.190 |
Why?
|
| Middle Aged | 181 | 2026 | 28511 | 3.180 |
Why?
|
| Aneurysm, False | 13 | 2025 | 85 | 3.100 |
Why?
|
| Aortic Rupture | 16 | 2023 | 109 | 2.960 |
Why?
|
| Cardiac Surgical Procedures | 25 | 2025 | 1157 | 2.900 |
Why?
|
| Reoperation | 36 | 2025 | 834 | 2.860 |
Why?
|
| Perfusion | 14 | 2022 | 211 | 2.720 |
Why?
|
| Aortic Valve Insufficiency | 9 | 2023 | 149 | 2.590 |
Why?
|
| Hospital Mortality | 33 | 2025 | 1066 | 2.560 |
Why?
|
| Risk Assessment | 54 | 2026 | 3694 | 2.510 |
Why?
|
| Male | 228 | 2026 | 64763 | 2.500 |
Why?
|
| Aortic Valve Stenosis | 18 | 2023 | 353 | 2.430 |
Why?
|
| Female | 212 | 2026 | 70550 | 2.300 |
Why?
|
| Hypothermia, Induced | 9 | 2019 | 171 | 2.280 |
Why?
|
| Heart Valve Prosthesis | 14 | 2023 | 302 | 2.240 |
Why?
|
| Brachiocephalic Trunk | 6 | 2017 | 35 | 2.080 |
Why?
|
| Replantation | 6 | 2019 | 51 | 2.050 |
Why?
|
| Kaplan-Meier Estimate | 22 | 2024 | 1082 | 2.000 |
Why?
|
| Heart Valve Diseases | 9 | 2019 | 168 | 1.970 |
Why?
|
| Aorta, Abdominal | 9 | 2020 | 95 | 1.950 |
Why?
|
| Heart Arrest, Induced | 7 | 2021 | 74 | 1.940 |
Why?
|
| Prosthesis Design | 27 | 2024 | 617 | 1.830 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 9 | 2016 | 41 | 1.790 |
Why?
|
| Aneurysm, Infected | 3 | 2022 | 23 | 1.780 |
Why?
|
| Stroke | 14 | 2022 | 1058 | 1.770 |
Why?
|
| Catheterization, Peripheral | 5 | 2017 | 126 | 1.700 |
Why?
|
| Transcatheter Aortic Valve Replacement | 10 | 2023 | 225 | 1.660 |
Why?
|
| Hospitals, Veterans | 8 | 2021 | 345 | 1.540 |
Why?
|
| Cerebrovascular Circulation | 11 | 2019 | 483 | 1.530 |
Why?
|
| Coronary Artery Disease | 12 | 2025 | 892 | 1.490 |
Why?
|
| Axillary Artery | 4 | 2017 | 31 | 1.480 |
Why?
|
| Acute Kidney Injury | 7 | 2026 | 696 | 1.460 |
Why?
|
| Prosthesis-Related Infections | 7 | 2022 | 187 | 1.390 |
Why?
|
| Postoperative Care | 5 | 2020 | 297 | 1.350 |
Why?
|
| Patient Readmission | 11 | 2025 | 431 | 1.350 |
Why?
|
| Aortography | 14 | 2023 | 151 | 1.340 |
Why?
|
| Renal Dialysis | 6 | 2026 | 949 | 1.280 |
Why?
|
| Renal Insufficiency | 8 | 2026 | 256 | 1.280 |
Why?
|
| Hypothermia | 3 | 2022 | 61 | 1.240 |
Why?
|
| Subclavian Artery | 4 | 2016 | 64 | 1.210 |
Why?
|
| Device Removal | 5 | 2021 | 225 | 1.210 |
Why?
|
| Spinal Cord Ischemia | 5 | 2019 | 31 | 1.200 |
Why?
|
| Acute Disease | 22 | 2025 | 1151 | 1.180 |
Why?
|
| Sternotomy | 5 | 2019 | 42 | 1.150 |
Why?
|
| Elective Surgical Procedures | 9 | 2026 | 162 | 1.090 |
Why?
|
| Logistic Models | 20 | 2026 | 1805 | 1.070 |
Why?
|
| Registries | 13 | 2025 | 1617 | 1.060 |
Why?
|
| Bioprosthesis | 11 | 2023 | 111 | 1.060 |
Why?
|
| Aged, 80 and over | 45 | 2023 | 6797 | 1.010 |
Why?
|
| Cardioplegic Solutions | 3 | 2021 | 18 | 1.000 |
Why?
|
| Adult | 67 | 2025 | 31238 | 0.980 |
Why?
|
| Thoracotomy | 5 | 2019 | 108 | 0.950 |
Why?
|
| Ischemia | 7 | 2022 | 358 | 0.950 |
Why?
|
| Thoracic Surgery | 10 | 2022 | 163 | 0.940 |
Why?
|
| Severity of Illness Index | 12 | 2023 | 3040 | 0.930 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 1290 | 0.910 |
Why?
|
| Survival Rate | 30 | 2020 | 2140 | 0.900 |
Why?
|
| Prospective Studies | 32 | 2024 | 6448 | 0.900 |
Why?
|
| Kidney | 5 | 2018 | 1283 | 0.880 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2020 | 2112 | 0.880 |
Why?
|
| Cardiovascular Surgical Procedures | 4 | 2016 | 42 | 0.850 |
Why?
|
| Heart Bypass, Left | 6 | 2008 | 15 | 0.810 |
Why?
|
| Databases, Factual | 13 | 2025 | 1228 | 0.810 |
Why?
|
| Follow-Up Studies | 34 | 2024 | 5199 | 0.810 |
Why?
|
| Congresses as Topic | 2 | 2016 | 185 | 0.780 |
Why?
|
| Prosthesis Failure | 7 | 2016 | 157 | 0.780 |
Why?
|
| Heart Ventricles | 2 | 2020 | 762 | 0.770 |
Why?
|
| Rare Diseases | 2 | 2023 | 207 | 0.770 |
Why?
|
| Viscera | 3 | 2014 | 56 | 0.760 |
Why?
|
| United States | 38 | 2025 | 11865 | 0.750 |
Why?
|
| Multivariate Analysis | 17 | 2019 | 1380 | 0.750 |
Why?
|
| Poverty | 2 | 2024 | 450 | 0.750 |
Why?
|
| Hospitals, Low-Volume | 3 | 2019 | 35 | 0.750 |
Why?
|
| Endocarditis | 6 | 2018 | 103 | 0.750 |
Why?
|
| Survival Analysis | 13 | 2019 | 1501 | 0.750 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2020 | 106 | 0.740 |
Why?
|
| Health Status Disparities | 1 | 2025 | 277 | 0.730 |
Why?
|
| Aneurysm | 3 | 2022 | 66 | 0.720 |
Why?
|
| Myocardial Infarction | 6 | 2023 | 1001 | 0.710 |
Why?
|
| Cardiopulmonary Bypass | 8 | 2025 | 359 | 0.700 |
Why?
|
| Hematoma | 2 | 2020 | 88 | 0.680 |
Why?
|
| Length of Stay | 16 | 2024 | 1396 | 0.670 |
Why?
|
| Peripheral Arterial Disease | 1 | 2025 | 321 | 0.660 |
Why?
|
| Propensity Score | 6 | 2024 | 272 | 0.660 |
Why?
|
| Sarcopenia | 1 | 2021 | 56 | 0.650 |
Why?
|
| Diffusion of Innovation | 3 | 2019 | 84 | 0.640 |
Why?
|
| Dissection | 1 | 2020 | 57 | 0.630 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2020 | 73 | 0.630 |
Why?
|
| Incidental Findings | 2 | 2019 | 124 | 0.630 |
Why?
|
| Pulmonary Valve | 1 | 2020 | 87 | 0.620 |
Why?
|
| Global Warming | 1 | 2019 | 4 | 0.600 |
Why?
|
| Brachial Artery | 1 | 2019 | 35 | 0.600 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2019 | 773 | 0.600 |
Why?
|
| Splenectomy | 1 | 2019 | 62 | 0.590 |
Why?
|
| Funnel Chest | 2 | 2012 | 33 | 0.590 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2019 | 15 | 0.590 |
Why?
|
| Mitral Valve | 3 | 2022 | 246 | 0.590 |
Why?
|
| Cardiology | 2 | 2016 | 510 | 0.590 |
Why?
|
| Arm | 1 | 2019 | 72 | 0.590 |
Why?
|
| Cardiac Catheterization | 5 | 2015 | 623 | 0.580 |
Why?
|
| Spinal Cord | 4 | 2021 | 262 | 0.580 |
Why?
|
| Quality of Life | 3 | 2021 | 2082 | 0.580 |
Why?
|
| Parents | 1 | 2025 | 1105 | 0.550 |
Why?
|
| Young Adult | 21 | 2025 | 10040 | 0.540 |
Why?
|
| Vena Cava, Inferior | 2 | 2016 | 95 | 0.530 |
Why?
|
| Surgeons | 5 | 2023 | 289 | 0.530 |
Why?
|
| Models, Statistical | 3 | 2010 | 482 | 0.530 |
Why?
|
| Perioperative Care | 1 | 2020 | 221 | 0.530 |
Why?
|
| Computed Tomography Angiography | 6 | 2020 | 215 | 0.530 |
Why?
|
| Texas | 17 | 2021 | 3635 | 0.520 |
Why?
|
| Hernia, Diaphragmatic, Traumatic | 1 | 2017 | 6 | 0.520 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2017 | 8 | 0.520 |
Why?
|
| Muscle, Smooth, Vascular | 10 | 2017 | 226 | 0.510 |
Why?
|
| Aortic Coarctation | 2 | 2020 | 96 | 0.510 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 336 | 0.510 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2019 | 180 | 0.510 |
Why?
|
| Calcinosis | 2 | 2016 | 181 | 0.510 |
Why?
|
| Chi-Square Distribution | 8 | 2016 | 563 | 0.500 |
Why?
|
| Chronic Disease | 7 | 2024 | 1236 | 0.500 |
Why?
|
| Celiac Artery | 1 | 2016 | 31 | 0.500 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 646 | 0.500 |
Why?
|
| Herniorrhaphy | 1 | 2017 | 72 | 0.490 |
Why?
|
| Thrombosis | 2 | 2019 | 498 | 0.490 |
Why?
|
| Vascular Diseases | 1 | 2018 | 153 | 0.490 |
Why?
|
| Extracorporeal Circulation | 3 | 2012 | 46 | 0.490 |
Why?
|
| Economic Competition | 1 | 2016 | 14 | 0.490 |
Why?
|
| Tracheostomy | 1 | 2019 | 211 | 0.490 |
Why?
|
| Anastomosis, Surgical | 6 | 2025 | 176 | 0.470 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1125 | 0.470 |
Why?
|
| Iatrogenic Disease | 2 | 2025 | 119 | 0.470 |
Why?
|
| Incidence | 15 | 2025 | 3336 | 0.470 |
Why?
|
| Tissue Adhesives | 3 | 2005 | 39 | 0.470 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 507 | 0.470 |
Why?
|
| Citrus sinensis | 1 | 2015 | 6 | 0.460 |
Why?
|
| Malus | 1 | 2015 | 12 | 0.460 |
Why?
|
| Socioeconomic Factors | 3 | 2024 | 896 | 0.460 |
Why?
|
| Pneumonectomy | 2 | 2014 | 147 | 0.460 |
Why?
|
| Preoperative Care | 5 | 2020 | 359 | 0.450 |
Why?
|
| Kidney Diseases | 2 | 2010 | 472 | 0.450 |
Why?
|
| Critical Care | 1 | 2020 | 685 | 0.450 |
Why?
|
| Suture Techniques | 2 | 2016 | 175 | 0.440 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 569 | 0.440 |
Why?
|
| Allografts | 4 | 2023 | 218 | 0.440 |
Why?
|
| Patient Care Team | 1 | 2019 | 558 | 0.430 |
Why?
|
| Microfilament Proteins | 6 | 2016 | 272 | 0.430 |
Why?
|
| Sex Factors | 6 | 2025 | 1342 | 0.420 |
Why?
|
| Pneumococcal Infections | 1 | 2016 | 279 | 0.420 |
Why?
|
| Heart Aneurysm | 1 | 2014 | 30 | 0.420 |
Why?
|
| Bronchial Fistula | 1 | 2014 | 23 | 0.420 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 389 | 0.410 |
Why?
|
| Hemodynamics | 8 | 2025 | 807 | 0.400 |
Why?
|
| History, 20th Century | 4 | 2021 | 360 | 0.400 |
Why?
|
| Pericardium | 1 | 2014 | 103 | 0.400 |
Why?
|
| Renal Circulation | 2 | 2014 | 41 | 0.390 |
Why?
|
| Hospitals | 3 | 2022 | 441 | 0.390 |
Why?
|
| Decision Making | 1 | 2018 | 692 | 0.390 |
Why?
|
| Monitoring, Intraoperative | 4 | 2010 | 129 | 0.390 |
Why?
|
| Adolescent | 24 | 2020 | 20818 | 0.390 |
Why?
|
| Societies, Medical | 4 | 2017 | 793 | 0.390 |
Why?
|
| Mammary Arteries | 2 | 2010 | 31 | 0.380 |
Why?
|
| Myocytes, Smooth Muscle | 10 | 2023 | 170 | 0.380 |
Why?
|
| Income | 2 | 2024 | 137 | 0.370 |
Why?
|
| Patient Discharge | 5 | 2024 | 510 | 0.370 |
Why?
|
| Cohort Studies | 12 | 2019 | 5095 | 0.370 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 223 | 0.370 |
Why?
|
| Isotonic Solutions | 2 | 2010 | 37 | 0.370 |
Why?
|
| Machine Learning | 4 | 2025 | 386 | 0.370 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 112 | 0.370 |
Why?
|
| Femoral Artery | 1 | 2012 | 135 | 0.360 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2009 | 74 | 0.360 |
Why?
|
| Atherosclerosis | 3 | 2017 | 953 | 0.360 |
Why?
|
| Social Class | 3 | 2025 | 206 | 0.360 |
Why?
|
| Matrix Metalloproteinases | 3 | 2020 | 62 | 0.360 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2007 | 194 | 0.350 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 2119 | 0.350 |
Why?
|
| Catheterization | 3 | 2019 | 226 | 0.350 |
Why?
|
| Odds Ratio | 8 | 2017 | 1215 | 0.340 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 675 | 0.340 |
Why?
|
| Potassium Compounds | 2 | 2008 | 7 | 0.340 |
Why?
|
| Age Factors | 8 | 2022 | 2841 | 0.330 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 421 | 0.320 |
Why?
|
| Paraparesis | 3 | 2022 | 8 | 0.320 |
Why?
|
| Sex Distribution | 5 | 2021 | 315 | 0.320 |
Why?
|
| Evoked Potentials, Motor | 1 | 2010 | 29 | 0.320 |
Why?
|
| Hypotension | 1 | 2012 | 182 | 0.320 |
Why?
|
| Angioplasty | 2 | 2008 | 66 | 0.310 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2008 | 185 | 0.300 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 851 | 0.300 |
Why?
|
| Veterans | 10 | 2016 | 1805 | 0.300 |
Why?
|
| Ciprofloxacin | 2 | 2020 | 63 | 0.300 |
Why?
|
| Forecasting | 3 | 2019 | 353 | 0.300 |
Why?
|
| Transplantation, Heterologous | 2 | 2011 | 257 | 0.300 |
Why?
|
| Cause of Death | 6 | 2017 | 504 | 0.300 |
Why?
|
| Inflammasomes | 3 | 2021 | 153 | 0.290 |
Why?
|
| Proportional Hazards Models | 9 | 2016 | 1405 | 0.290 |
Why?
|
| Internship and Residency | 7 | 2021 | 1216 | 0.290 |
Why?
|
| Ontario | 2 | 2019 | 84 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2022 | 480 | 0.280 |
Why?
|
| Serum Albumin | 2 | 2011 | 102 | 0.280 |
Why?
|
| Fibrillin-1 | 6 | 2020 | 60 | 0.280 |
Why?
|
| Cerebrospinal Fluid | 2 | 2013 | 100 | 0.270 |
Why?
|
| Comorbidity | 9 | 2022 | 1587 | 0.270 |
Why?
|
| Cells, Cultured | 17 | 2023 | 2906 | 0.270 |
Why?
|
| Hemostasis, Surgical | 3 | 2012 | 34 | 0.270 |
Why?
|
| Glutaral | 3 | 2007 | 8 | 0.270 |
Why?
|
| Carotid Artery, Common | 1 | 2007 | 59 | 0.260 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2020 | 126 | 0.260 |
Why?
|
| Proteins | 3 | 2012 | 1016 | 0.260 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2021 | 106 | 0.260 |
Why?
|
| Linear Models | 4 | 2013 | 689 | 0.260 |
Why?
|
| Heart Defects, Congenital | 2 | 2021 | 1876 | 0.250 |
Why?
|
| Vocal Cord Paralysis | 2 | 2018 | 66 | 0.250 |
Why?
|
| Animals | 26 | 2023 | 33981 | 0.240 |
Why?
|
| Morbidity | 2 | 2021 | 260 | 0.240 |
Why?
|
| Recovery of Function | 3 | 2019 | 446 | 0.240 |
Why?
|
| Endothelium, Vascular | 6 | 2009 | 471 | 0.240 |
Why?
|
| Clinical Competence | 6 | 2023 | 1055 | 0.240 |
Why?
|
| Support Vector Machine | 1 | 2026 | 28 | 0.240 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2020 | 246 | 0.240 |
Why?
|
| Nomograms | 1 | 2026 | 40 | 0.230 |
Why?
|
| Patient Selection | 6 | 2021 | 723 | 0.230 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2025 | 36 | 0.220 |
Why?
|
| Vasoplegia | 1 | 2025 | 19 | 0.220 |
Why?
|
| Constriction | 3 | 2016 | 46 | 0.220 |
Why?
|
| Pandemics | 3 | 2021 | 1158 | 0.210 |
Why?
|
| Angiography | 3 | 2014 | 184 | 0.210 |
Why?
|
| Exercise Test | 2 | 2023 | 235 | 0.210 |
Why?
|
| Arterial Pressure | 1 | 2025 | 131 | 0.210 |
Why?
|
| Mesenteric Arteries | 1 | 2004 | 50 | 0.210 |
Why?
|
| Renal Artery Obstruction | 1 | 2004 | 38 | 0.210 |
Why?
|
| Prognosis | 7 | 2019 | 4910 | 0.210 |
Why?
|
| Caspase 1 | 3 | 2021 | 49 | 0.210 |
Why?
|
| Actins | 3 | 2015 | 316 | 0.210 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2022 | 294 | 0.210 |
Why?
|
| Workload | 2 | 2008 | 149 | 0.210 |
Why?
|
| Signal Transduction | 8 | 2021 | 4697 | 0.200 |
Why?
|
| Compassionate Use Trials | 1 | 2023 | 17 | 0.200 |
Why?
|
| Recurrence | 3 | 2024 | 1486 | 0.200 |
Why?
|
| Social Responsibility | 1 | 2004 | 84 | 0.200 |
Why?
|
| Gene Expression Regulation | 6 | 2021 | 2355 | 0.200 |
Why?
|
| Postoperative Period | 3 | 2021 | 330 | 0.200 |
Why?
|
| Vascular Remodeling | 2 | 2020 | 47 | 0.200 |
Why?
|
| Spirometry | 1 | 2023 | 93 | 0.200 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2023 | 12 | 0.200 |
Why?
|
| Personal Satisfaction | 1 | 2004 | 104 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 3 | 2022 | 454 | 0.200 |
Why?
|
| Radiography | 4 | 2016 | 751 | 0.200 |
Why?
|
| Intraoperative Period | 2 | 2015 | 66 | 0.200 |
Why?
|
| Procollagen-Proline Dioxygenase | 3 | 2008 | 31 | 0.190 |
Why?
|
| Azides | 1 | 2022 | 11 | 0.190 |
Why?
|
| Hemostatics | 1 | 2003 | 58 | 0.190 |
Why?
|
| Forced Expiratory Volume | 1 | 2023 | 178 | 0.190 |
Why?
|
| Deoxyglucose | 1 | 2022 | 41 | 0.190 |
Why?
|
| Hemoglobins | 2 | 2019 | 287 | 0.190 |
Why?
|
| Aneurysm, Ruptured | 1 | 2003 | 36 | 0.190 |
Why?
|
| Pacemaker, Artificial | 2 | 2023 | 194 | 0.190 |
Why?
|
| Educational Status | 1 | 2024 | 274 | 0.190 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 45 | 0.190 |
Why?
|
| Lung | 2 | 2023 | 1549 | 0.190 |
Why?
|
| Foreign-Body Migration | 1 | 2003 | 64 | 0.190 |
Why?
|
| Polyethylene Terephthalates | 2 | 2016 | 22 | 0.180 |
Why?
|
| State Medicine | 1 | 2022 | 23 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 10 | 2022 | 4715 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2008 | 243 | 0.180 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 967 | 0.180 |
Why?
|
| Swine | 6 | 2009 | 1187 | 0.180 |
Why?
|
| Foundations | 1 | 2021 | 24 | 0.180 |
Why?
|
| Factor Analysis, Statistical | 1 | 2022 | 232 | 0.180 |
Why?
|
| Financing, Government | 1 | 2021 | 33 | 0.180 |
Why?
|
| DNA | 5 | 2023 | 1420 | 0.180 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 623 | 0.180 |
Why?
|
| Body Temperature | 1 | 2002 | 126 | 0.180 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 1892 | 0.170 |
Why?
|
| Disease Progression | 4 | 2020 | 2212 | 0.170 |
Why?
|
| Mice, Knockout | 9 | 2022 | 3836 | 0.170 |
Why?
|
| General Surgery | 1 | 2004 | 225 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 136 | 0.170 |
Why?
|
| Child | 9 | 2023 | 26215 | 0.170 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 727 | 0.170 |
Why?
|
| Ulcer | 1 | 2021 | 51 | 0.170 |
Why?
|
| Trachea | 1 | 2003 | 207 | 0.170 |
Why?
|
| Catheters | 1 | 2021 | 84 | 0.170 |
Why?
|
| RNA, Small Interfering | 6 | 2009 | 667 | 0.170 |
Why?
|
| Endoleak | 2 | 2022 | 43 | 0.170 |
Why?
|
| Up-Regulation | 7 | 2009 | 836 | 0.170 |
Why?
|
| Computational Biology | 1 | 2026 | 868 | 0.170 |
Why?
|
| Puerperal Disorders | 1 | 2021 | 44 | 0.160 |
Why?
|
| Hospitals, High-Volume | 2 | 2018 | 43 | 0.160 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 358 | 0.160 |
Why?
|
| Surge Capacity | 1 | 2020 | 9 | 0.160 |
Why?
|
| Mutation, Missense | 2 | 2019 | 931 | 0.160 |
Why?
|
| Loeys-Dietz Syndrome | 2 | 2021 | 42 | 0.160 |
Why?
|
| Brain | 5 | 2021 | 3201 | 0.160 |
Why?
|
| ADAMTS4 Protein | 2 | 2017 | 9 | 0.160 |
Why?
|
| Intestinal Fistula | 1 | 2020 | 22 | 0.160 |
Why?
|
| Case-Control Studies | 10 | 2021 | 3393 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2006 | 254 | 0.160 |
Why?
|
| Coinfection | 1 | 2022 | 188 | 0.160 |
Why?
|
| Vascular Fistula | 1 | 2020 | 27 | 0.160 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 31 | 0.160 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2009 | 125 | 0.160 |
Why?
|
| Emergency Treatment | 2 | 2016 | 82 | 0.160 |
Why?
|
| Angiotensin II | 5 | 2021 | 130 | 0.160 |
Why?
|
| Dilatation, Pathologic | 2 | 2020 | 79 | 0.160 |
Why?
|
| Sulfones | 1 | 2020 | 72 | 0.160 |
Why?
|
| Temperature | 2 | 2021 | 289 | 0.160 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2021 | 110 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2012 | 256 | 0.150 |
Why?
|
| Growth and Development | 1 | 2019 | 20 | 0.150 |
Why?
|
| Cost Savings | 1 | 2020 | 79 | 0.150 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 264 | 0.150 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 230 | 0.150 |
Why?
|
| Statistics, Nonparametric | 3 | 2016 | 426 | 0.150 |
Why?
|
| Splenic Diseases | 1 | 2019 | 29 | 0.150 |
Why?
|
| Cytosol | 1 | 2019 | 137 | 0.150 |
Why?
|
| Hemoperfusion | 1 | 2019 | 5 | 0.150 |
Why?
|
| Adipokines | 6 | 2020 | 120 | 0.150 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2020 | 100 | 0.150 |
Why?
|
| Thioredoxins | 2 | 2009 | 28 | 0.150 |
Why?
|
| Tunica Intima | 1 | 2019 | 61 | 0.150 |
Why?
|
| Sex Characteristics | 1 | 2021 | 325 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2026 | 3428 | 0.150 |
Why?
|
| Hemolysis | 1 | 2019 | 89 | 0.150 |
Why?
|
| Smad4 Protein | 1 | 2019 | 58 | 0.140 |
Why?
|
| Forkhead Transcription Factors | 3 | 2012 | 373 | 0.140 |
Why?
|
| Spleen | 1 | 2019 | 258 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 2564 | 0.140 |
Why?
|
| Spine | 1 | 2019 | 154 | 0.140 |
Why?
|
| Probability | 5 | 2009 | 307 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 153 | 0.140 |
Why?
|
| Spices | 1 | 2017 | 4 | 0.140 |
Why?
|
| Friends | 1 | 2017 | 18 | 0.140 |
Why?
|
| Chylothorax | 1 | 2018 | 27 | 0.130 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1833 | 0.130 |
Why?
|
| Versicans | 1 | 2017 | 15 | 0.130 |
Why?
|
| Disease Models, Animal | 7 | 2021 | 4682 | 0.130 |
Why?
|
| Long Term Adverse Effects | 1 | 2017 | 13 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 298 | 0.130 |
Why?
|
| Transplantation, Homologous | 2 | 2018 | 669 | 0.130 |
Why?
|
| Intraoperative Care | 3 | 2010 | 122 | 0.130 |
Why?
|
| Mice | 12 | 2023 | 18267 | 0.130 |
Why?
|
| Risk Adjustment | 1 | 2017 | 57 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2020 | 403 | 0.130 |
Why?
|
| Seasons | 2 | 2009 | 334 | 0.130 |
Why?
|
| Laryngoplasty | 1 | 2017 | 28 | 0.130 |
Why?
|
| Heart Arrest | 1 | 2021 | 377 | 0.130 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1977 | 0.130 |
Why?
|
| Drainage | 2 | 2013 | 248 | 0.130 |
Why?
|
| Apoptosis | 6 | 2020 | 1844 | 0.130 |
Why?
|
| Echocardiography | 8 | 2016 | 1127 | 0.130 |
Why?
|
| Coronary Disease | 2 | 2012 | 628 | 0.130 |
Why?
|
| Education, Medical, Graduate | 4 | 2021 | 551 | 0.130 |
Why?
|
| Mutation | 7 | 2015 | 6138 | 0.130 |
Why?
|
| Endocarditis, Bacterial | 1 | 2018 | 128 | 0.120 |
Why?
|
| Vasoconstriction | 1 | 2017 | 94 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 237 | 0.120 |
Why?
|
| Age Distribution | 3 | 2013 | 424 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2008 | 165 | 0.120 |
Why?
|
| Reactive Oxygen Species | 2 | 2009 | 521 | 0.120 |
Why?
|
| Conservative Treatment | 1 | 2016 | 47 | 0.120 |
Why?
|
| Patient Positioning | 1 | 2016 | 49 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 3 | 2006 | 305 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2020 | 134 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 1031 | 0.120 |
Why?
|
| Endothelial Cells | 4 | 2006 | 524 | 0.120 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2020 | 157 | 0.120 |
Why?
|
| Specialties, Surgical | 1 | 2017 | 90 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2021 | 1605 | 0.120 |
Why?
|
| Family | 1 | 2019 | 583 | 0.120 |
Why?
|
| Fibrillins | 5 | 2015 | 28 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 484 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 646 | 0.110 |
Why?
|
| Coronary Angiography | 2 | 2016 | 451 | 0.110 |
Why?
|
| Peptide Hormones | 1 | 2016 | 70 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2021 | 561 | 0.110 |
Why?
|
| Algorithms | 2 | 2021 | 1682 | 0.110 |
Why?
|
| Hospital Bed Capacity | 2 | 2012 | 29 | 0.110 |
Why?
|
| Anesthesia, General | 1 | 2016 | 143 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 643 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 364 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2019 | 292 | 0.110 |
Why?
|
| Intraoperative Complications | 3 | 2018 | 155 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 243 | 0.110 |
Why?
|
| Fasting | 1 | 2016 | 306 | 0.110 |
Why?
|
| Consensus | 4 | 2021 | 532 | 0.110 |
Why?
|
| Health Status Indicators | 2 | 2012 | 111 | 0.110 |
Why?
|
| Cytomegalovirus | 2 | 2006 | 258 | 0.110 |
Why?
|
| Chemistry, Clinical | 1 | 2014 | 10 | 0.100 |
Why?
|
| Insulin | 3 | 2016 | 1148 | 0.100 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2014 | 20 | 0.100 |
Why?
|
| Aspirin | 1 | 2015 | 215 | 0.100 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2014 | 39 | 0.100 |
Why?
|
| Muscle Proteins | 1 | 2017 | 404 | 0.100 |
Why?
|
| Debridement | 1 | 2014 | 87 | 0.100 |
Why?
|
| Hospitals, Teaching | 2 | 2011 | 109 | 0.100 |
Why?
|
| Heart Diseases | 2 | 2009 | 504 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 277 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2014 | 193 | 0.100 |
Why?
|
| Heterografts | 1 | 2014 | 193 | 0.100 |
Why?
|
| Cell Differentiation | 3 | 2021 | 1935 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 1234 | 0.100 |
Why?
|
| Faculty, Medical | 1 | 2017 | 279 | 0.100 |
Why?
|
| Nephrectomy | 1 | 2014 | 156 | 0.100 |
Why?
|
| Mitral Valve Prolapse | 1 | 2013 | 34 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2015 | 276 | 0.100 |
Why?
|
| Cyclic GMP-Dependent Protein Kinase Type I | 1 | 2013 | 17 | 0.100 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2016 | 156 | 0.100 |
Why?
|
| Cattle | 1 | 2014 | 501 | 0.100 |
Why?
|
| Constriction, Pathologic | 3 | 2020 | 227 | 0.100 |
Why?
|
| Mortality | 1 | 2015 | 258 | 0.100 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2012 | 10 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2025 | 2303 | 0.100 |
Why?
|
| Confusion | 1 | 2012 | 14 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 485 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 699 | 0.100 |
Why?
|
| Activities of Daily Living | 2 | 2012 | 378 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 632 | 0.090 |
Why?
|
| Health Care Surveys | 2 | 2010 | 277 | 0.090 |
Why?
|
| Proteolysis | 3 | 2019 | 197 | 0.090 |
Why?
|
| Lung Injury | 1 | 2014 | 123 | 0.090 |
Why?
|
| ADAM Proteins | 1 | 2012 | 82 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2016 | 688 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 210 | 0.090 |
Why?
|
| Receptor, Notch1 | 1 | 2012 | 79 | 0.090 |
Why?
|
| Phenotype | 6 | 2023 | 4482 | 0.090 |
Why?
|
| Elastic Tissue | 3 | 2020 | 18 | 0.090 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 56 | 0.090 |
Why?
|
| Palmitic Acid | 2 | 2009 | 28 | 0.090 |
Why?
|
| Lung Diseases | 2 | 2014 | 396 | 0.090 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2010 | 85 | 0.090 |
Why?
|
| Vascular Grafting | 1 | 2012 | 48 | 0.090 |
Why?
|
| Emergencies | 2 | 2023 | 176 | 0.090 |
Why?
|
| Oxygen | 2 | 2006 | 551 | 0.090 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 304 | 0.090 |
Why?
|
| Stroke Volume | 1 | 2014 | 541 | 0.090 |
Why?
|
| Job Description | 1 | 2011 | 9 | 0.090 |
Why?
|
| Fibroblasts | 4 | 2019 | 860 | 0.090 |
Why?
|
| Hypoalbuminemia | 1 | 2011 | 16 | 0.090 |
Why?
|
| Biopsy | 1 | 2014 | 1243 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2013 | 291 | 0.080 |
Why?
|
| Health Resources | 1 | 2012 | 126 | 0.080 |
Why?
|
| Career Mobility | 1 | 2011 | 51 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2011 | 144 | 0.080 |
Why?
|
| Elastin | 2 | 2013 | 31 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2011 | 148 | 0.080 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2011 | 79 | 0.080 |
Why?
|
| Biomarkers | 4 | 2019 | 3400 | 0.080 |
Why?
|
| Chromosome Duplication | 1 | 2011 | 147 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2010 | 74 | 0.080 |
Why?
|
| Endarterectomy, Carotid | 1 | 2011 | 75 | 0.080 |
Why?
|
| Heart-Assist Devices | 2 | 2011 | 1014 | 0.080 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 549 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 1324 | 0.080 |
Why?
|
| Hospital Charges | 1 | 2010 | 68 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 234 | 0.080 |
Why?
|
| Collagen | 2 | 2022 | 277 | 0.080 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2012 | 37 | 0.080 |
Why?
|
| Spinal Cord Diseases | 2 | 2007 | 34 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2012 | 292 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2010 | 308 | 0.080 |
Why?
|
| Acute Coronary Syndrome | 1 | 2013 | 247 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2011 | 351 | 0.080 |
Why?
|
| Chromatin | 2 | 2023 | 503 | 0.080 |
Why?
|
| Vascular Patency | 1 | 2010 | 180 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 1842 | 0.080 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2009 | 40 | 0.080 |
Why?
|
| Academic Medical Centers | 4 | 2017 | 318 | 0.080 |
Why?
|
| Mentors | 1 | 2011 | 167 | 0.080 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 230 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2010 | 319 | 0.080 |
Why?
|
| Brain Ischemia | 1 | 2012 | 268 | 0.080 |
Why?
|
| Glucose | 2 | 2016 | 855 | 0.070 |
Why?
|
| Safety | 1 | 2010 | 215 | 0.070 |
Why?
|
| Amputees | 1 | 2009 | 9 | 0.070 |
Why?
|
| Macrophages | 3 | 2020 | 659 | 0.070 |
Why?
|
| Hospital Costs | 1 | 2010 | 182 | 0.070 |
Why?
|
| Saphenous Vein | 1 | 2009 | 49 | 0.070 |
Why?
|
| Work Schedule Tolerance | 1 | 2009 | 39 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2010 | 439 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 1264 | 0.070 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 734 | 0.070 |
Why?
|
| Quality of Health Care | 2 | 2009 | 407 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2019 | 1457 | 0.070 |
Why?
|
| Moyamoya Disease | 1 | 2009 | 45 | 0.070 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2008 | 15 | 0.070 |
Why?
|
| Angioscopy | 1 | 2008 | 2 | 0.070 |
Why?
|
| RNA, Messenger | 7 | 2009 | 2566 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 1269 | 0.070 |
Why?
|
| Gene Expression | 4 | 2021 | 1492 | 0.070 |
Why?
|
| Octamer Transcription Factors | 1 | 2008 | 9 | 0.070 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2008 | 18 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2012 | 493 | 0.070 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 136 | 0.070 |
Why?
|
| Iliac Artery | 1 | 2008 | 63 | 0.070 |
Why?
|
| ROC Curve | 1 | 2010 | 607 | 0.070 |
Why?
|
| Renal Artery | 1 | 2008 | 70 | 0.070 |
Why?
|
| Coronary Restenosis | 1 | 2008 | 19 | 0.070 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 55 | 0.070 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2009 | 170 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 312 | 0.070 |
Why?
|
| Surgery Department, Hospital | 1 | 2008 | 20 | 0.070 |
Why?
|
| Thoracic Injuries | 1 | 2008 | 84 | 0.070 |
Why?
|
| Alloys | 1 | 2007 | 12 | 0.070 |
Why?
|
| Pregnancy | 2 | 2021 | 7402 | 0.070 |
Why?
|
| Phrenic Nerve | 1 | 2007 | 10 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2021 | 2849 | 0.070 |
Why?
|
| Histones | 2 | 2008 | 547 | 0.070 |
Why?
|
| Neural Conduction | 1 | 2007 | 83 | 0.070 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2007 | 12 | 0.070 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2007 | 8 | 0.070 |
Why?
|
| Polytetrafluoroethylene | 1 | 2007 | 61 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2007 | 90 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2008 | 190 | 0.070 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 3 | 2013 | 29 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2008 | 131 | 0.060 |
Why?
|
| Vertebral Artery | 1 | 2007 | 18 | 0.060 |
Why?
|
| Radiography, Interventional | 1 | 2007 | 87 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2007 | 141 | 0.060 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2007 | 33 | 0.060 |
Why?
|
| Lumbosacral Region | 1 | 2006 | 22 | 0.060 |
Why?
|
| Cyclonic Storms | 1 | 2008 | 75 | 0.060 |
Why?
|
| Oxyhemoglobins | 1 | 2006 | 25 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2009 | 377 | 0.060 |
Why?
|
| Ligation | 1 | 2006 | 133 | 0.060 |
Why?
|
| Collagen Type III | 1 | 2006 | 23 | 0.060 |
Why?
|
| Life Tables | 1 | 2006 | 26 | 0.060 |
Why?
|
| Thorax | 1 | 2006 | 66 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2008 | 186 | 0.060 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2006 | 112 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1612 | 0.060 |
Why?
|
| Molecular Sequence Data | 4 | 2016 | 3497 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2007 | 219 | 0.060 |
Why?
|
| Exome | 2 | 2026 | 1076 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2005 | 333 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2006 | 57 | 0.060 |
Why?
|
| Shock, Cardiogenic | 1 | 2008 | 173 | 0.060 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 913 | 0.060 |
Why?
|
| Credentialing | 1 | 2006 | 17 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2006 | 111 | 0.060 |
Why?
|
| Frail Elderly | 1 | 2007 | 107 | 0.060 |
Why?
|
| Resistin | 1 | 2006 | 30 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2007 | 362 | 0.060 |
Why?
|
| Cardiovascular Agents | 2 | 2021 | 87 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 324 | 0.060 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 116 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2007 | 205 | 0.060 |
Why?
|
| Needles | 1 | 2005 | 49 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2005 | 11 | 0.060 |
Why?
|
| Heart Atria | 1 | 2008 | 335 | 0.060 |
Why?
|
| Angiopoietin-2 | 1 | 2005 | 13 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 419 | 0.060 |
Why?
|
| RNA | 1 | 2008 | 520 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 4 | 2012 | 1229 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 731 | 0.050 |
Why?
|
| Hindlimb | 1 | 2005 | 72 | 0.050 |
Why?
|
| Anticoagulants | 2 | 2023 | 605 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2026 | 740 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2020 | 15016 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2008 | 542 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2006 | 1399 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2008 | 555 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2009 | 1006 | 0.050 |
Why?
|
| Pedigree | 3 | 2013 | 1688 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2005 | 220 | 0.050 |
Why?
|
| HIV | 1 | 2005 | 177 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 195 | 0.050 |
Why?
|
| Motion | 1 | 2023 | 37 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2012 | 940 | 0.050 |
Why?
|
| Drug Approval | 1 | 2003 | 46 | 0.050 |
Why?
|
| Obesity | 2 | 2016 | 2387 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 784 | 0.050 |
Why?
|
| Education, Medical, Continuing | 2 | 2017 | 130 | 0.050 |
Why?
|
| Hand | 1 | 2023 | 95 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 231 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 165 | 0.050 |
Why?
|
| Splanchnic Circulation | 1 | 2022 | 49 | 0.050 |
Why?
|
| Mesenteric Ischemia | 1 | 2022 | 30 | 0.050 |
Why?
|
| Heart Neoplasms | 1 | 2003 | 108 | 0.050 |
Why?
|
| Career Choice | 1 | 2004 | 165 | 0.050 |
Why?
|
| Anaerobic Threshold | 1 | 2022 | 10 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 2343 | 0.050 |
Why?
|
| Serum Albumin, Bovine | 1 | 2002 | 37 | 0.050 |
Why?
|
| Epigenomics | 1 | 2023 | 182 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 1547 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2008 | 228 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 2113 | 0.050 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2023 | 133 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2003 | 177 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2022 | 188 | 0.040 |
Why?
|
| Muscle Contraction | 2 | 2013 | 146 | 0.040 |
Why?
|
| Introns | 3 | 2008 | 281 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2016 | 813 | 0.040 |
Why?
|
| Accreditation | 1 | 2021 | 87 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2022 | 298 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2003 | 180 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2008 | 833 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2012 | 1580 | 0.040 |
Why?
|
| Genes, Reporter | 2 | 2016 | 342 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2407 | 0.040 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2020 | 8 | 0.040 |
Why?
|
| Forkhead Box Protein O1 | 2 | 2012 | 99 | 0.040 |
Why?
|
| Sinus of Valsalva | 1 | 2021 | 32 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 1215 | 0.040 |
Why?
|
| Enzyme Activation | 3 | 2006 | 582 | 0.040 |
Why?
|
| Cell Division | 1 | 2002 | 721 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 398 | 0.040 |
Why?
|
| Inpatients | 2 | 2017 | 558 | 0.040 |
Why?
|
| Indenes | 1 | 2020 | 10 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 2021 | 154 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2020 | 21 | 0.040 |
Why?
|
| China | 1 | 2021 | 280 | 0.040 |
Why?
|
| Analgesics | 1 | 2021 | 120 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 150 | 0.040 |
Why?
|
| Furans | 1 | 2020 | 28 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2007 | 1019 | 0.040 |
Why?
|
| Ion Channels | 1 | 2021 | 198 | 0.040 |
Why?
|
| Organ Size | 1 | 2021 | 421 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2005 | 720 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 266 | 0.040 |
Why?
|
| Transfection | 3 | 2006 | 963 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 3 | 2011 | 1722 | 0.040 |
Why?
|
| Uncertainty | 1 | 2020 | 97 | 0.040 |
Why?
|
| Adsorption | 1 | 2019 | 33 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2026 | 1555 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2026 | 1101 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2006 | 2454 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 230 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 438 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1618 | 0.040 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 1 | 2018 | 14 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 507 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 1395 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2012 | 413 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2019 | 177 | 0.030 |
Why?
|
| Wound Healing | 1 | 2002 | 481 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 765 | 0.030 |
Why?
|
| Efficiency | 2 | 2009 | 74 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2019 | 238 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2010 | 788 | 0.030 |
Why?
|
| Leadership | 1 | 2020 | 244 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2020 | 298 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2012 | 655 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 407 | 0.030 |
Why?
|
| Random Allocation | 1 | 2018 | 416 | 0.030 |
Why?
|
| Injections | 1 | 2017 | 110 | 0.030 |
Why?
|
| Glyburide | 1 | 2017 | 21 | 0.030 |
Why?
|
| Syndrome | 1 | 2020 | 1162 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 97 | 0.030 |
Why?
|
| DNA Primers | 2 | 2009 | 606 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.030 |
Why?
|
| Plasmids | 2 | 2009 | 451 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2012 | 522 | 0.030 |
Why?
|
| Balloon Valvuloplasty | 1 | 2016 | 26 | 0.030 |
Why?
|
| Radiation Chimera | 1 | 2016 | 16 | 0.030 |
Why?
|
| Activating Transcription Factor 2 | 2 | 2006 | 16 | 0.030 |
Why?
|
| Progeria | 1 | 2016 | 17 | 0.030 |
Why?
|
| Pericytes | 1 | 2016 | 18 | 0.030 |
Why?
|
| Global Health | 1 | 2021 | 628 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2016 | 72 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 82 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 270 | 0.030 |
Why?
|
| Heart Conduction System | 1 | 2017 | 161 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 62 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 200 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 265 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 232 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2008 | 698 | 0.030 |
Why?
|
| Motivation | 1 | 2018 | 330 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2016 | 96 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 159 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2016 | 229 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2019 | 545 | 0.030 |
Why?
|
| Gene Silencing | 2 | 2006 | 231 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2009 | 750 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 320 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2016 | 586 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 318 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 729 | 0.030 |
Why?
|
| Cell Nucleus | 2 | 2008 | 569 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1129 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 4017 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 266 | 0.030 |
Why?
|
| Citric Acid | 1 | 2014 | 45 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2013 | 35 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2013 | 42 | 0.030 |
Why?
|
| Fibrillin-2 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2016 | 255 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 2014 | 47 | 0.030 |
Why?
|
| Prevalence | 2 | 2011 | 2694 | 0.030 |
Why?
|
| Myosin Light Chains | 1 | 2013 | 11 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2013 | 93 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 315 | 0.020 |
Why?
|
| Hypertension | 2 | 2014 | 1354 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 1623 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2013 | 90 | 0.020 |
Why?
|
| Binding Sites | 2 | 2006 | 1149 | 0.020 |
Why?
|
| Aortitis | 1 | 2012 | 6 | 0.020 |
Why?
|
| ADAMTS1 Protein | 1 | 2012 | 15 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2016 | 391 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2012 | 92 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2012 | 97 | 0.020 |
Why?
|
| Drug-Eluting Stents | 1 | 2013 | 62 | 0.020 |
Why?
|
| Heparin | 1 | 2014 | 204 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 60 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2012 | 112 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2012 | 51 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 872 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 235 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 64 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2012 | 37 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 812 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2013 | 414 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 95 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2017 | 976 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 326 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 2012 | 100 | 0.020 |
Why?
|
| Genotyping Techniques | 1 | 2011 | 110 | 0.020 |
Why?
|
| Base Sequence | 2 | 2006 | 2764 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2012 | 188 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 75 | 0.020 |
Why?
|
| Stem Cells | 1 | 2016 | 715 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 679 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 362 | 0.020 |
Why?
|
| Perception | 1 | 2012 | 231 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 319 | 0.020 |
Why?
|
| Coronary Stenosis | 1 | 2011 | 78 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 752 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 2011 | 106 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2011 | 356 | 0.020 |
Why?
|
| Cardiac Output, Low | 1 | 2010 | 59 | 0.020 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2009 | 18 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2009 | 90 | 0.020 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2009 | 31 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2010 | 79 | 0.020 |
Why?
|
| Ribonucleotides | 1 | 2009 | 31 | 0.020 |
Why?
|
| Mexico | 1 | 2009 | 188 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2011 | 364 | 0.020 |
Why?
|
| Transplants | 1 | 2009 | 38 | 0.020 |
Why?
|
| Risk Management | 1 | 2009 | 65 | 0.020 |
Why?
|
| Family Health | 1 | 2009 | 242 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1666 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2009 | 187 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 622 | 0.020 |
Why?
|
| Liver | 1 | 2016 | 1799 | 0.020 |
Why?
|
| Protein Deglycase DJ-1 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Leg | 1 | 2009 | 121 | 0.020 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2008 | 34 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 20 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 912 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2009 | 419 | 0.020 |
Why?
|
| Utilization Review | 1 | 2008 | 39 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 190 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 442 | 0.020 |
Why?
|
| Sinoatrial Node | 1 | 2007 | 27 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2008 | 111 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 136 | 0.020 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2008 | 61 | 0.020 |
Why?
|
| Albumins | 1 | 2007 | 88 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2007 | 112 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2924 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 1928 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 765 | 0.020 |
Why?
|
| Necrosis | 1 | 2007 | 194 | 0.020 |
Why?
|
| Compliance | 1 | 2006 | 18 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2006 | 21 | 0.020 |
Why?
|
| Linoleic Acid | 1 | 2006 | 22 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 84 | 0.020 |
Why?
|
| Cicatrix | 1 | 2007 | 125 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 2006 | 56 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 88 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2006 | 126 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2012 | 1681 | 0.010 |
Why?
|
| Oncogene Protein v-akt | 1 | 2005 | 33 | 0.010 |
Why?
|
| Luciferases | 1 | 2006 | 127 | 0.010 |
Why?
|
| 3-Phosphoinositide-Dependent Protein Kinases | 1 | 2005 | 18 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 106 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2009 | 1059 | 0.010 |
Why?
|
| Response Elements | 1 | 2006 | 104 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 168 | 0.010 |
Why?
|
| Caspases | 1 | 2006 | 156 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2008 | 505 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 584 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 146 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2006 | 292 | 0.010 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2004 | 6 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2009 | 968 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 3807 | 0.010 |
Why?
|
| Systole | 1 | 2005 | 195 | 0.010 |
Why?
|
| Heart Rate | 1 | 2007 | 576 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 2005 | 154 | 0.010 |
Why?
|
| Rabbits | 1 | 2005 | 574 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 410 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 778 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 2483 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2008 | 1093 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 615 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 902 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2580 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1391 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2006 | 684 | 0.010 |
Why?
|
| Smoking | 1 | 2006 | 923 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 2606 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2003 | 1019 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 1478 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2003 | 1279 | 0.010 |
Why?
|
| Heart Failure | 1 | 2009 | 2335 | 0.010 |
Why?
|
| Neoplasms | 1 | 2004 | 2955 | 0.000 |
Why?
|